CHICAGO, Sept. 21 /PRNewswire-FirstCall/ -- The Female Health Company (OTC:FHCO) (BULLETIN BOARD: FHCO) announced today that its second generation Female Condom FC-2 has received registration by the Indian governmental authorities. This permits the Company and its Indian partner Hindustan Latex Limited (HLL) to initiate sales of FC-2 in India. India is now reported to have the highest number of HIV positive people in the world. Although such cases are less than 1% of its 1 billion population, the Indian government, through its National Aids Control Organization, is aggressively implementing prevention programs. Nearly 1 million FC-1 female condoms have been shipped to India in the last year for use in such programs. In May of this year the Company announced that it had signed a Memorandum of Understanding with its partner Hindustan Latex Limited (HLL) to jointly manufacture FC-2 in India. HLL is an Indian Government company (website: http://www.hindlatex.com/ ) with an annual male condom manufacturing capacity of 1 billion units. In addition to sales to the Indian government, HLL is launching the female condom (FC-1) to consumers using the trade name Confidom (website: http://www.confidom.com/ ) on a city by city basis. It is now available in Bangalore, Chennai, and Kolcutta, as well as on-line, with a series of additional city launches planned. The Company expects the development of FC-2 will result in significantly lower manufacturing and capital costs, and this ultimately will result in lower prices at high volume with the objective of accelerating market penetration. The Female Health Company, based in Chicago, owns certain worldwide rights to FC Female Condom(TM) including patents which have been issued in the United States, United Kingdom, Japan, France, Italy, Germany, Spain, The People's Republic of China, Canada, New Zealand, South Korea and Australia. FC Female Condom(TM) is the only available product approved by the FDA under a woman's control that provides dual protection against unintended pregnancy and sexually transmitted diseases including HIV/AIDS. "Safe Harbor" statement under the Private Securities Litigation Reform Action of 1995: The statements in this release which are not historical fact are forward-looking statements based upon the Company's current plan and strategies, and reflect the Company's current assessment of the risks and uncertainties related to its business, including such things as product demand and market acceptance; the economic and business environment and the impact of government pressures; currency risks; capacity; efficiency and supply constraints; and other risks detailed in the Company's press releases, shareholder communication and Securities and Exchange Commission filings. Actual events affecting the Company and the impact of such events on the Company's operations may vary from those currently anticipated. For more information about the Female Health Company, dial toll-free via fax, 1-800-PRO-INFO and enter company code "FHCO". Also, visit the Company's web site at http://www.femalehealth.com/ and http://www.femalecondom.org/ . If you would like to be added to the Company's e-mail alert list, please send an e-mail to . DATASOURCE: The Female Health Company CONTACT: Investors, William R. Gargiulo, Jr., +1-231-526-1244, or Donna Felch, +1-312-595-9742, both of The Female Health Company Web site: http://www.femalehealth.com/ http://www.femalecondom.org/ http://www.hindlatex.com/ http://www.confidom.com/

Copyright